Alpha Lipoic Acid and Diabetes Mellitus: Potential Effects on Peripheral Neuropathy
Status:
Completed
Trial end date:
2020-12-23
Target enrollment:
Participant gender:
Summary
Patients with type 2 DM who are following will be enrolled into the study. Two visits were
scheduled for data collection, physical examination and laboratory testing of the patients:
the first prior to initiation of alpha lipoic acid (ALA) administration (baseline visit) and
the second at the end of the third month following initiation of ALA (2nd visit).